Portfolio

We are interested in licensing and developing therapeutics across all disease areas that are at the lead optimization through IND-enabling stages of development.

Orca Pharmaceuticals

Source: New York University

Target: RORy Inhibitors

Researchers: Dan Littman, Juh Hun

Indication: Psoriasis

Brickwell Biotech logo Astra Zeneca logo
Kodosil Bio

Source: BioAtla

Target: IL-22 Inhibitors

Researchers: Bill Boyle

Indication: Inflammatory Bowel Diseases

Dual Therapeutics

Source: Mt. Sinai School of Medicine, Case Western Reserve University

Target: PP2a Activators

Researchers: Goutham Narla, Michael Ohlmeyer, Matthew Galsky

Indication: Cancer

Bristol Meyers Squibb logo
OptiKira

Source: University of California, San Francisco; University of Washington

Target: IRE1a Inhibitors

Researchers: Feroz Papa, Scott Oakes, Bradley Backes, Dustin Maly

Indication: Retinitis Pigmentosa

Sujana Biotech

Source: Case Western Reserve University

Target: GBIba Inhibitor of Mac-1

Researchers: Daniel Simon, Edward Plow, Yunmei Wang

Indication: Anti-inflammatory

Z53 Therapeutics

Source: Rutgers University, Upstate Medical University (SUNY)

Target: Zinc Metallochaperones

Researchers: Darren Carpizo, David Kimball

Indication: Cancer

Allinaire Therapeutics

Source: Indiana University

Target: Confidential

Researchers: Irina Petrache, Matthias Clauss

Indication: Chronic Obstructive Pulmonary Disease

SapVax

Source: University of Auckland

Target: Tumor Antigen Platform (NY-ESO-1, Epstein-Barr Virus)

Researchers: Rod Dunbar, Margaret Brimble

Indication: Immuno-Oncology

Nynex Therapeutics

Source: University of Michigan

Target: USP9x Inhibitors

Researchers: Moshe Talpaz, Hollis Showalter, Nicolas Donato, Matthew Young

Indication: Cancer

Inclera Therapeutics

A development company that helps scientists advance their technology towards commercialization